ATS 3f Aortic Bioprosthesis Offers Unique Approach To Enhanced Durability
ATS Medical acknowledged the positive clinical results of aortic root dimensions study presented by noted cardiologist Dr. Xu Yu Jin.
Dr. Jin's presentation at the recent Advanced Cardiac Techniques in Surgery conference sponsored by the Lenox Hill Heart and Vascular Institute of New York was entitled "Implantation Technique and Implication of 3f Stentless Valve Design for Aortic Root Geometry."
In a prospective echocardiographic study of 150 patients, the author studied aortic root dimensions in patients receiving the ATS 3f(R) Aortic Bioprosthesis with its single suture line/3 tab fixation, stentless valves implanted with conventional double suture line techniques and native valve aortic roots. Among the conclusions, Dr. Jin reported that valves implanted with double suture-line techniques led to significantly smaller aortic sinus diameter and formed tubular aortic root geometry.
The ATS 3f valve with no direct sutures in the aortic sinus fully preserved the native aortic root geometry without compromising valve hemodynamics or left ventricular mass.
James L. Cox, MD, Emeritus Evarts A. Graham Professor of Surgery, Washington University School of Medicine, St. Louis, Missouri, and principal in the development of the ATS 3f(R) Aortic Bioprosthesis offered his comments on Dr. Jin's observations. "The original objective of the ATS 3f, form follows function, valve was to reproduce the function, not the form of the normal native aortic valve.
This approach dictates that if the function is accurately reproduced, the normal form of the aortic valve will slavishly follow. Dr. Jin's study documents that the normal form of the aortic root is best preserved/reestablished by implantation of the ATS 3f valve, confirming the accuracy of the original concept. Preserving the aortic root in its natural form is but one more indication that the ATS 3f aortic valve prosthesis is fundamentally different from all previous valve prostheses and strongly suggests that its longevity will be superior to all previous artificial tissue valves," noted Dr. Cox.